CLAIMS

I Claim:

- 1. A composition comprising 0% to about 29% w/w of *cis*-clomiphene and about 100% to about 71% *trans*-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients.
- 2. A composition comprising *cis*-clomiphene and *trans*-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients and wherein the ratio of *trans*-clomiphene and *cis*-clomiphene is greater than 71/29.
- 3. A composition consisting essentially of *trans*-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients.
- 4. A method for treating wasting in a mammal, comprising administering to the mammal an effective amount of a composition comprising *cis*-clomiphene and *trans*-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients, wherein the ratio of *trans*-clomiphene to *cis*-clomiphene is greater than 71/29.
- 5. A method for modulating muscle mass muscle mass in a mammal, comprising administering to the mammal an effective amount of a composition comprising *cis*-clomiphene and *trans*-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients, wherein the ratio of *trans*-clomiphene to *cis*-clomiphene in said composition is greater than 71/29.
- 6. A method for modulating cholesterol levels in a mammal, comprising administering to the mammal an effective amount of a composition comprising *cis*-clomiphene and *trans*-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients, wherein the ratio of *trans*-clomiphene to *cis*-clomiphene is greater than 71/29.
- 7. A method for treating lipodystrophy in a mammal, comprising administering to the mammal an effective amount of a composition comprising *cis*-clomiphene and *trans*-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and

optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients, wherein the ratio of *trans*-clomiphene to *cis*-clomiphene is greater than 71/29.

- 8. A method for modulating lymphocyte levels in a mammal, comprising administering to the mammal an effective amount of a composition comprising *cis*-clomiphene and *trans*-clomiphene or analogs thereof or pharmaceutically acceptable salts or solvates thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients, wherein the ratio of *trans*-clomiphene to *cis*-clomiphene is greater than 71/29.
- 9. The method of claim 8, wherein the lymphocyte levels modulated are CD4⁺ T lymphocyte levels are increased.
- 10. The method of any one of claims 4-9 wherein the composition consists essentially of an effective amount of *trans*-clomiphene or an analog thereof or a pharmaceutically effective salt or solvate thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients.
 - 11. The method of claim 10, wherein the mammal is a human.
 - 12. The method of claim 11 wherein the human is infected with HIV
 - 13. The method of any one of claims 4-9 where the mammal is a human.
 - 14. The methods of claim 13 wherein the human is infected with HIV